Price
$0.30
Increased by 0.00%
Dollar volume (20D)
207.10 K
ADR%
9.00
Earnings report date
May 14, 2025
Shares float
1.07 B
Shares short
4.59 M [0.43%]
Shares outstanding
263.92 M
Market cap
79.89 M
Beta
2.85
Price/earnings
N/A
20D range
0.20 0.32
50D range
0.20 0.61
200D range
0.20 1.48

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.

It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer.

The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520).

It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center.

Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Mar 20, 25 -0.24
Increased by +0.25%
-0.15
Decreased by -55.45%
Nov 14, 24 -0.01
Increased by +95.00%
-0.18
Increased by +94.54%
Aug 12, 24 0.24
Increased by +204.35%
-0.07
Increased by +442.86%
May 15, 24 -0.18
Decreased by -1.90 K%
-0.10
Decreased by -80.00%
Mar 6, 24 -0.24
Decreased by -33.33%
-0.10
Decreased by -140.00%
Nov 8, 23 -0.20
Increased by +16.67%
-0.12
Decreased by -66.67%
Aug 9, 23 -0.23
Increased by +17.86%
-0.13
Decreased by -76.92%
May 12, 23 0.01
Increased by +103.33%
-0.15
Increased by +106.67%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 24 3.22 M
Increased by +1.28 K%
-74.22 M
Decreased by -53.55%
Decreased by -2.30 K%
Increased by +88.90%
Sep 30, 24 40.90 M
Increased by +458.83%
-17.62 M
Increased by +61.37%
Decreased by -43.07%
Increased by +93.09%
Jun 30, 24 128.23 M
Increased by +2.40 K%
69.52 M
Increased by +425.03%
Increased by +54.22%
Increased by +113.00%
Mar 31, 24 5.68 M
Decreased by -88.07%
-48.50 M
Decreased by -4.78 K%
Decreased by -854.23%
Decreased by -39.35 K%
Dec 31, 23 233.01 K
Decreased by -97.89%
-48.33 M
Decreased by -65.24%
Decreased by -20.74 K%
Decreased by -7.72 K%
Sep 30, 23 7.32 M
Increased by +4.45%
-45.60 M
Decreased by -10.09%
Decreased by -623.05%
Decreased by -5.40%
Jun 30, 23 5.13 M
Decreased by -7.37%
-21.39 M
Increased by +51.96%
Decreased by -416.94%
Increased by +48.14%
Mar 31, 23 47.60 M
Increased by +1.23 K%
1.04 M
Increased by +102.06%
Increased by +2.18%
Increased by +100.15%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY